Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes
研究方案:最低有效低剂量:抗人胸腺细胞球蛋白(MELD-ATG):II期剂量范围研究,评估抗胸腺细胞球蛋白(ATG)在1型糖尿病确诊后6周内的疗效
期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2021-053669
Wilhelm-Benartzi, Charlotte S; Miller, Sarah E; Bruggraber, Sylvaine; Picton, Diane; Wilson, Mark; Gatley, Katrina; Chhabra, Anita; Marcovecchio, M Loredana; Hendriks, A Emile J; Morobé, Hilde; Chmura, Piotr Jaroslaw; Bond, Simon; Aschemeier-Fuchs, Bärbel; Knip, Mikael; Tree, Timothy; Overbergh, Lut; Pall, Jaivier; Arnaud, Olivier; Haller, Michael J; Nitsche, Almut; Schulte, Anke M; Mathieu, Chantal; Mander, Adrian; Dunger, David